Receptor protein tyrosine phosphatase ζ as a therapeutic target for glioblastoma therapy

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 3, 2004, Pages 211-220

  Müller, Sabine ^a   Lamszus, Katrin ^b   Nikolich, Karoly ^a   Westphal, Manfred ^b  

^a AGY Therapeutics Inc   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Glioblastoma; Immunotherapy; Migration; Pleiotropin; Receptor protein tyrosine phosphatase

Indexed keywords

BORTEZOMIB; CASPASE 3; CYCLIN A; CYCLIN B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6; MONOCLONAL ANTIBODY BC2; MONOCLONAL ANTIBODY L8A4; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLEIOTROPHIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RETINOBLASTOMA PROTEIN; SEMAXANIB; TEMSIROLIMUS; TENASCIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ASTROCYTOMA; BINDING KINETICS; BRACHYTHERAPY; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOLOGY; DEATH; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INHIBITION KINETICS; MOLECULAR GENETICS; PATIENT CARE; PROTEIN FUNCTION; RADIOSURGERY; REVIEW; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; IMMUNIZATION, PASSIVE; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 3042717659     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.3.211     Document Type: Review

References (101)

1. BORING CC, SQUIRES TS, TONG T, MONTGOMERY S: Cancer statistics, 1994. CA Cancer J. Clin. (1994) 44:7-26.
2. DAVIS FG, KUPELIAN V, FREELS S, MCCARTHY B, SURAWICZ T: Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncol. (2001) 3:152-158.
3. POLLACK IF: Brain rumors in children. N. Engl. J. Med. (1994) 331:1500-1507.
4. PACKER RJ, VEZINA G: Pediatric glial neoplasms including brain-stem gliomas. Semin.Oncol. (1994) 21:260-272.
5. KLEIHUES P, OHGAKI H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. (1999) 1:44-51.
6. KLEIHUES P, OHGAKI H: Phenotype versus genotype in the evolution of astrocytic brain tumors. Toxicol. Pathol. (2000) 28:164-170.
7. ROSSER T, PACKER RJ: Intracranial neoplasms in children with neurofibromatosis 1. J. Child Neurol. (2002) 17:630-637; discussion 646-651.
8. SHEPHERD CW, GOMEZ MR, LIE JT, CROWSON CS: Causes of death in patients with tuberous sclerosis. Mayo. Clin. Proc. (1991) 66:792-796.
9. MALKIN D, LI FP, STRONG LC et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 250:1233-1238.
10. LAWS ER, PARNEY IF, HUANG W et al.: Survival following surgery and prognostic fiicrors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. (2003) 99:467-473.
11. KRAMM CM, SENA-ESTEVES M, BARNETT FH et al.: Gene therapy for brain tumors. Brain Pathol. (1995) 5:345-381.
12. SUGAWA N, UEDA S, NAKAGAWA Y et al.: An antisense EGFR oligodeoxynucleotide enveloped in Lipofection induces growth inhibition in human malignant gliomas in vitro. J. Neurooncol. (1998) 39:237-244.
13. BIGNER DD, BROWN MT, FRIEDMAN AH et al.: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. (1998) 16:2202-2212.
14. CHANG SM, KUHN JG, IAN ROBINS H et al.: A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Invest. New Drugs (2003) 21:429-433.
15. DEININGER MH, WEINSCHENK T, MORGALLA MH, MEYERMANN R, SCHLUESENER HJ: Release of regulators of angiogenesis following Hypocrellin-A and -B photodynamic therapy of human brain tumor cells. Biechem. Biophys. Res. Commun. (2002) 298:520-530.
16. BREM S, COTRAN R, FOLKMAN J: Tumor angiogenesis: a quantitative method for histologic grading. J. Natl. Cancer Inst. (1972) 48:347-356.
17. HADDAD SF, MOORE SA, SCHELPER RI, GOEKEN JA: Vascular smooth muscle hyperplasia underlies the formation of glomeruloid vascular structures of glioblastoma multiforme. J. Neuropathol. Exp. Neurol. (1992) 51:488-492.
18. LAMSZUS K, KUNKEL P, WESTPHAL M: Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. (2003) 88:169-177.
19. GIESE A, WESTPHAL M: Glioma invasion in the central nervous system. Neurosurgery (1996) 39:235-250.
20. BERENS ME, GIESE A: '...those left behind.' Biology and oncology of invasive glioma cells. Neoplasia (1999) 1:208-219.
21. MATSUKADO Y, MACCARTY CS, KERNOHAN JW. The growth of glioblastoma. multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J. Neurosurg. (1961) 18:636-644.
22. MARIANI L, BEAUDRY C, MCDONOUGH WS et al.: Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J. Neurooncol. (2001) 53:161-176.
23. MARIANI L, MCDONOUGH WS, HOELZINGER DB et al.: Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res. (2001) 61:4190-4196.
24. WATANABE K, TACHIBANA O, SATA K et al.: Overexpression of the EGF receptor and p53 mutations am mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. (1996) 6:217-223; discussion 23-24.
25. VON DEIMLING A, LOUIS DN, VON AMMON K et al.: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. (1992) 77:295-301.
26. REIFENBERGER G, LIU L, ICHIMURA K, SCHMIDT EE, COLLINS VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant glioma without p53 mutations. Cancer Res. (1993) 53:2736-2739.
27. TOHMA Y, GRATAS C, BIERNAT W et al.: PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. (1998) 57:684-689.
28. YOON KS, LEE MC, KANG SS et al.: p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J. Korean Med. Sci. (2001) 16:481-488.
29. ZAUBERMAN A, FLUSBERG D, HAUPT Y, BARAK Y, OREN M: A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. (1995) 23:2584-2592.
30. ULBRICHT U, BROCKMANN MA, AIGNER A et al.: Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J. Neuropathol. Exp. Neurol. (2003) 62:1265-1275.
31. KRUEGER NX, SAITO H: A human transmembrane protein-tyrosine-phosphatase, PTP ζ, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc. Natl. Acad. Sci USA (1992) 89:7417-7421.
32. LEVY JB, CANOLL PD, SELVENNOINEN O et al.: The cloning of a rcceptor-type protein tyrosine phosphatase expressed in the central nervous system. J. Biol. Chem. (1993) 268:10573-10581.
33. TONKS NK, CHARBONNEAU H, DILTZ CD, FISCHER EH, WALSH KA: Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase. Biochemistry (Mosc.) (1988) 27:8695-8701.
34. BIXBY JL: Receptor tyrosine phosphatases in axon growth and guidance. Neuroreport (2000) 11:R5-R10.
35. ANDERSEN JN, MORTENSEN OH, PETERS GH et al.: Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. (2001) 21:7117-7136.
36. HOOFT VAN HUIJSDUIJNEN R: Protein tyrosine phosphatases: counting the trees in the forest. Gene (1998) 225:1-8.
37. BARNEA G, SIEVENNOINEN O, SHAANAN B et al.: Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP γ defines a new subfamily of receptor tyrosine phosphatases. Mol. Cell. Biol. (1993) 13:1497-1506.
38. JOHNSON KG, VAN VACTOR D: Receptor protein tyrosine phosphatases in nervous system development. Physiol. Rev. (2003) 83:1-24.
39. MAEDA N, HAMANAKA H, OOHIRA A, NODA M: Purification, characterization and developmental expression of a brain-specific chondroitin sulfate proteoglycan, 6B4 proteoglycan/phosphacan. Neuroscience (1995) 67:23-35.
40. CANOLL PD, BARNEA G, LEVY JB et al.: The expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system. Brain Res. Dev. Brain Res. (1993) 75:293-298.
41. MILEV P, FRIEDLANDER DR, SAKURAI T et al.: Interactions of the chondroitin sulfate protoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules. J. Cell Biol. (1994) 127:1703-1715.
42. MAEDA N, NODA. M: Involvement of receptor-like protein tyrosine phosphataase ζ/RPTPβ and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J. Cell Biol. (1998) 142:203-216.
43. CANOLL PD, PETANCESKA S, SCHLESSINGER J, MUSACCHIO JM: Three forms of RPTP-β are differentially expressed during gliogenesis in the developing rat brain and during glial cell differentiation in culture. J. Neurosci. Res. (1996) 44:199-215.
44. GARWOOD J, HECK N, REICHARDT F, FAISSNER A. Phosphacan short isoform, a novel non-proteoglycan variant of phosphacan/receptor protein tyrosine phosphatase-β, interacts with neuronal receptors and promotes neurite outgrowth. J. Biol. Chem. (2003) 278:24164-24173.
45. HARROCH S, PALMERI M, ROSENBLUTH J et al.: No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase β. Mol. Cell. Biol. (2000) 20:7706-7715.
46. HARROCH S, FURTADO GC, BRUECK W et al.: A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat. Genet. (2002) 32:411-414.
47. LI J, TULLAI JW, YU WH, SALTON SR: Regulated expression during development and following sciatic nerve injury of mRNAs encoding the receptor tyrosine phosphatase HPTPζ/RPTPβ. Brain Res Mol. Brain Res. (1998) 60:77-88.
48. MAUREL P, RAUCH U, FLAD M, MARGOLIS RK, MARGOLIS RU: Phosphacan, a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell-adhesion molecules, is an exracellular variant of a receptor-type protein tyrosine phosphatase. Proc. Natl. Acad. Sci. USA (1994) 91:2512-2516.
49. MILEV P, CHIBA A, HARING M et al.: High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-ζ/β with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. J. Biol. Chem. (1998) 273:6998-7005.
50. ADAMSKY K, SCHILLING J, GARWOOD J, FAISSNER A, PELES E: Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase β (RPTPβ) to tenascin C. Oncogene (2001) 20-609-618.
51. GRUMET M, MILEV P, SAKURAI T et al.: Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J. Biol. Chem. (1994) 269:12142-12146.
52. MILEV P, MONNERIE H, POPP S, MARGOLIS RK, MARGOLIS RU: The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity J. Biol. Chem. (1998) 273:21439-21442.
53. PELES E, NATIV M, CAMPBELL PL et al.: The carbonic anhydrase domain of receptor tyrosine phosphatase β is a functional ligand for the axonal cell recognition molecule contactin. Cell (1995) 82:251-260.
54. MENG K, RODRIGUEZ-PENA A, DIMITROV T et al.: Pleiotrophin signals increased tyrosine phosphorylation of β β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphate β/ζ. Proc. Natl. Acad. Sci. USA (2000) 97:2603-2608.
55. KAWACHI H, FUJIKAWA A, MAEDA N, NODA M: Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase ζ /β by the γ-substrate-trapping system. Proc. Natl. Acad. Sci. USA (2001) 98:6593-6598.
56. KAWACHI H, TAMURA H, WATAKABE I et al.: Protein tyrosine phosphatase zeta/RPTPβ interacts with PSD-95/SAP90 family; Brain Res. Mol. Brain Res. (1999) 72:47-54.
57. RATCLIFFE CF, QU Y, MCCORMICK KA et al.: A sodium channel signaling complex: modulation by associated receptor protein tyrosine phosphatase β. Nat. Neurosci. (2000) 3:437-444.
58. BILWES AM, DEN HERTOG J, HUNTERT, NOEL JP: Structural basis for inhibition of receptor protein-tyrosine phosphatase-α by dimerization. Nature (1996) 382:555-559.
59. MILNER PG, LI YS, HOFFMAN RM et al.: A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem. Biophys. Res. Commun. (1989) 165:1096-1103.
60. RAUVALA H: An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. (1989) 8:2933-2941.
61. DEUEL TF, ZHANG N, YEH HJ, SILOS-SANTIAGO I, WANG ZY Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem Biophys. (2002) 397:162-171.
62. SILOS-SANTIAGO I, YEH HJ, GURRIERI MA et al.: Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neurat-glial interactions during development and in maturity. J. Neurobiol. (1996) 31:283-296.
63. CHAUHAN AK, LI YS, DEUEL TF: Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Natl. Acad. Sci. USA (1993) 90:679-682.
64. WELLSTEIN A, FANG W3, KHATRI A et al.: A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J. Biol. Chem. (1992) 267:2582-2587.
65. KURTZ A, SCHULTE AM, WELLSTEIN A: Pleiotrophin and midkine in normal development and tumor biology. Crit. Rev. Oncog. (1995) 6:151-177.
66. FANG W, HARTMANN N, CHOW DT, RIEGEL AT, WELLSTEIN A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J. Biol. Chem. (1992) 267:25889-25897.
67. YEH HJ, HE YY, XU J, HSU CY, DEUEL TF: Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J. Neurosci. (1998) 18:3699-3707.
68. MULLER S, KUNKEL P, LAMSZUS K et al.: A role for receptor tyrosine phosphatase ζ in glioma cell migration. Oncogene (2003) 22:6661-6668.
69. SCHMIDT NO, WESTPHAL M, HAGEL C et al.: Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer (1999) 84:10-18.
70. BURGER PC, DUBOIS PJ, SCHOLD SC Jr et al.: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. (1983) 58:159-169.
71. EARNEST FT, KELLY PJ, SCHEITHAUER BW et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy Radiology (1988) 166:823-327.
72. WESTPHAL M, BLACK P: Perspectives of cellular and molecular neurosurgery. J. Neurooncol. (in press).
73. WESTPHAL M, HILT DC, BORTEY E et al.: A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. (2003) 5:79-88.
74. WESTPHAL M, LAMSZUS K, HILT D: Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir. Suppl. (2003) 88:61-67.
75. MERLO A, MUELLER-BRAND J, MAECKE HR: Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir. Suppl. (2003) 88:83-91.
76. GOETZ C, RACHINGER W, POEPPERL G et al.: Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir. Suppl. (2003) 88:69-75.
77. WUST P, HILDEBRANDT B, SREENIVASA G et al.: Hyperthemia in combined treatment of cancer. Lancet Oncol. (2002) 3:487-497.
78. LIBERMANN TA, NUSBAUM HR, RAZON N et al.: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 313:144-147.
79. MISHIMA K, JOHNS TG, LUWOR RB et al.: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. (2001) 61:5349-5354.
80. KURPAD SN, ZHAO XG, WIKSTRAND CJ et al.: Tumor antigens in astrocytic gliomas. Glia (1995) 15:244-256.
81. LORIMER IA, KEPPLER-HAFKEMEYER A, BEERS RA et al.: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. USA (1996) 93:14815-14820.
82. SAMPSON JH, CROTTY LE, LEE S et al.: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci USA (2000) 97:7503-7508.
83. BROWN MT, COLEMAN RE, FRIEDMAN AH et al.: Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res. (1996) 2:963-972.
84. ZALUTSKY MR, ARCHER GE, GARG PK, BATRA SK, BIGNER DD: Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl. Med. Biol. (1996) 23:449-458.
85. ZALUTSKY MR, ZHAO XG, ALSTON KL, BIGNER D: High-level production of α-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J. Nucl. Med. (2001) 42:1508-1515.
86. MERLO A, JERMANN E, HAUSMANN O et al.: Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int. J. Cancer (1997) 71:810-816.
87. RIVA P, ARISTA A, FRANCESCHI G et al.: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. (1995) 55 (23 Suppl.):5952-5956.
88. LEE Y, BULLARD DE, HUMPHREY PA et al.: Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. (1988) 48:2904-2910.
89. LEE YS, BULLARD DE, ZALUTSKY MR et al.: Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled routine monoclonal antibody in a human glioma xenograft model. Cancer Res. (1988) 48:559-566.
90. ZALUTSKY MR, MOSELEY RP, BENJAMIN JC et al.: Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. (1990) 50:4105-4110.
91. COKGOR I, AKABANI G, KUAN CT et al.: Phase I trial results of iodine-131-laeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2000) 18:3862-3872.
92. REARDON DA, AKABANI G, COLEMAN RE et al.: Phase II trial of routine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patient, with newly diagnosed malignant gliomas. J. Clin. Oncol. (2002) 20-1389-1397.
93. VAIDYANATHAN G, AFFLECK D, ZALUTSKY MR: Monoclonal antibody F(ab′)2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates. in vivo comparison of iodinated and astatinated fragment,. Nucl. Med. Biol. (1994) 21:105-110.
94. STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359:1011-1018.
95. RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22:133-142.
96. HUANG S, HOUGHTON PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig.Drugs (2002) 3:295-304.
97. KUNKEL P, ULBRICHT U, BOHLEN P et al.: Inhibition of glioma angiogenesis and growth in invo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res.(2001) 61:6624-6628.
98. MENDEL DB, SCHRECK RE, WEST DC et al.: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. (2000) 6:4848-4858.
99. MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15:29-41.
100. VOORHEES PM, DEES EC, O'NEIL B, ORLOWSKI RZ: The proteasome as a target for cancer therapy Clin. Cancer Res. (2003) 9:6316-6325.
101. LING YH, LIEBES L, JIANG JD et al.: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. (2003) 9:1145-1154.